About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- Adults with overweight/obesity, without diabetes; 57 sites, 10 countries (Canada, Denmark, Finland, Ireland, Japan, Poland, Serbia, South Africa, UK, USA)
- Sample size
- 706 randomised (about 100 per cagrilintide dose group, 99 liraglutide, 101 placebo)
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Sponsor-funded (Novo Nordisk); phase 2, not yet independently replicated as a standalone-agent trial.
Cited in
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.